selected scholarly activity
-
books
- Who Expert Committee on Biological Standardization.. Ed. 927. 2005
-
chapters
- WHO Expert Committee on Biological Standardization Sixty-seventh report. WHO Technical Report Series. 1-591. 2017
-
conferences
- The fraction of recombinant factor VIII unable to bind VWF is inactive. Haemophilia. 562-562. 2011
- Loss of ATP secretion contributes to the decreased responses of stored platelets to thrombin. Transfusion. 166A-166A. 2008
- Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR.. Blood. 1845-1845. 2004
- Either reducing or increasing the molecular volume of recombinant factor IX accelerates its overall clearance in a mouse model of Hemophilia B. Transfusion. 64A-65A. 2004
- Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology. 565-573. 2004
- Partial correction of the hemophilic phenotype in mice implanted with encapsulated human primary myoblasts secreting FIX. Molecular Therapy. S64-S64. 2004
- WHO Expert Committee on Biological Standardization.. WHO Technical Report Series. 1-backcover. 2004
- Cleavage of protease-activated receptor 1(PAR-1) by a platelet protease and thrombin: Modulation by soybean trypsin inhibitor, glycoprotein IB(GPIB), and anti-protease-activated receptor antibodies.. Transfusion. 104S-104S. 2000
- Therapeutic levels of human factor VIII in mice implanted with encapsulated recombinant myoblasts: Potential for gene therapy of hemophilia A. Transfusion. 1S-1S. 2000
- Biology of the hypercoagulable state following major trauma.. Blood. 240A-241A. 1999
- A trypsin-like platelet protease must generate PAR-1 residues 1-41 and PAR-1 tethered ligand to optimize propagation of platelet activation. Thrombosis and Haemostasis. 821-821. 1999
- Biology of the hypercoagulable state following major trauma. Thrombosis and Haemostasis. 405-405. 1999
- Calcium dependency of conformational changes in the EGF-1 region upon activation, but not active site inhibition, of human FVII. Thrombosis and Haemostasis. 466-466. 1999
- Cleavage of protease-activated receptor-1 (PAR-1) and platelet activation by alpha- and gamma-thrombins. Thrombosis and Haemostasis. 817-817. 1999
- Glycoprotein Ib (GPIb) modulates protein tyrosine phosphorylation to enhance platelet protease-activated receptor-1 (PAR-1) cleavage by a-thrombin. Thrombosis and Haemostasis. 817-817. 1999
- Statins, thrombin suppression, and hypothrombotic states. Thrombosis and Haemostasis. 191-191. 1999
- Sustained delivery of therapeutic levels of human factor IX in nude hemophilic mice implanted with encapsulated mouse myoblasts secreting human factor IX. Thrombosis and Haemostasis. 279-279. 1999
- Unactivated platelets provide factor IX necessary to optimize propagation of tissue factor (TF)-dependent coagulation. Thrombosis and Haemostasis. 713-713. 1999
- Both activation and active site occupation of human factor VII alter conformation of the first EGF-life domain.. Blood. 41A-41A. 1998
- Misfolding of the first epidermal growth factor domain results in decreased cellular secretion of factor VII. Thrombosis and Haemostasis. P1651-P1651. 1997
- Relationship between cleavage of the 7-transmembrane receptor on platelets and platelet activation by alpha-thrombin. Thrombosis and Haemostasis. PS253-PS253. 1997
- Catalytically equivalent doses of heparin and dermatan sulphate inhibit platelet-dependent prothrombinase formation to the same extent in plasma.. Blood. 3507-3507. 1995
- Thrombin-mediated platelet activation is due to the cleavage of the cloned thrombin receptor and independent of platelet glycoprotein Ib.. Blood. 2180-2180. 1995
- FACTOR-XA-ANTITHROMBIN-III ENDOGENOUS TO PLASMA - RELATIONSHIP TO PROTHROMBIN ACTIVATION IN-VIVO. Thrombosis and Haemostasis. 1250-1250. 1995
- INHIBITION OF THROMBIN-INDUCED PLATELET ACTIVATION BY SYNTHETIC ANTI-THROMBINS IN PLASMA. Thrombosis and Haemostasis. 1451-1451. 1995
- SITES OF TISSUE FACTOR-DEPENDENT PLASMA COAGULATION SUBJECT TO INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR. Thrombosis and Haemostasis. 943-943. 1995
- PLATELETS ARE THE PRIMARY SOURCE OF FACTOR VA FOR PROTHROMBINASE FORMATION IN PLATELET-RICH PLASMA. Blood. A191-A191. 1994
- THROMBIN-MEDIATED EVENTS IMPLICATED IN POSTTHROMBOTIC RECOVERY. Angiogenesis. 253-263. 1994
- CONSEQUENCES OF THE INTERACTIONS OF FIBRINOGEN, FIBRIN-I AND GLYCOSAMINOGLYCANS ON PROTHROMBIN ACTIVATION IN HUMAN PLASMA. Thrombosis and Haemostasis. 1260-1260. 1993
- CONTRAST-MEDIA INDUCES THROMBIN GENERATION DURING PTCA. Thrombosis and Haemostasis. 1014-1014. 1993
- DERMATAN SULFATE PREVENTS PROTHROMBIN CONSUMPTION DURING CARDIOPULMONARY BYPASS MORE EFFECTIVELY THAN HEPARIN. Thrombosis and Haemostasis. 890-890. 1993
- EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA AND VESSEL WALL OCCLUSION. Thrombosis and Haemostasis. 807-807. 1993
- EFFECTS OF SELECTIVE THROMBIN OR FACTOR-XA INHIBITORS ON THE ASSEMBLY OF PLATELET-BOUND PROTHROMBINASE IN PLASMA. Thrombosis and Haemostasis. 812-812. 1993
- EVIDENCE FOR HEPARIN COFACTOR-II (HCII) AS A PHYSIOLOGICAL INHIBITOR OF THROMBIN. Thrombosis and Haemostasis. 899-899. 1993
- EVIDENCE FOR PROTHROMBIN ACTIVATION AND IMPAIRED THROMBIN INHIBITION IN CANCER-PATIENTS. Thrombosis and Haemostasis. 573-573. 1993
- FACTOR-VII HAMILTON - A NOVEL TYPE-2 MUTATION LOCATED AT RESIDUE-57 IN THE 1ST EGF DOMAIN OF HUMAN FACTOR-VII. Thrombosis and Haemostasis. 1291-1291. 1993
- INACTIVATION OF FACTOR-VIIIA BY FACTOR-XA. Thrombosis and Haemostasis. 1087-1087. 1993
- INACTIVATION OF FACTOR-VIIIA BY THROMBIN. Thrombosis and Haemostasis. 1087-1087. 1993
- SIMULTANEOUS INHIBITION OF THROMBIN BY ATIII AND HCII AND PREVENTION OF THROMBUS FORMATION AND GROWTH - RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE. Thrombosis and Haemostasis. 667-667. 1993
- THROMBIN GENERATION DURING CARDIAC-SURGERY - IS HEPARIN THE IDEAL ANTICOAGULANT. Thrombosis and Haemostasis. 654-654. 1993
- EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA. Thrombosis Research. S72-S72. 1993
- MECHANISMS FOR THE ANTITHROMBOTIC EFFECTS OF GLYCOSAMINOGLYCANS. Thrombosis Research. S161-S161. 1993
- RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE ON PREVENTION OF THROMBUS FORMATION AND GROWTH. Thrombosis Research. S161-S161. 1993
- ANTITHROMBIN-III INDEPENDENT THROMBIN INHIBITORS PREVENT THROMBUS GROWTH MORE EFFECTIVELY THAN HEPARIN - IMPLICATIONS FOR ANTITHROMBOTIC THERAPY. Thrombosis and Haemostasis. 829-829. 1991
- DERMATAN SULFATE ANTICOAGULATION DURING CARDIOPULMONARY BYPASS REDUCES BLEEDING AND ELIMINATES THE NEED OF PROTAMINE NEUTRALIZATION. Thrombosis and Haemostasis. 863-863. 1991
- DERMATAN SULFATE INCREASES TPA-INDUCED THROMBOLYSIS WITHOUT INCREASING BLEEDING IN RABBITS. Thrombosis and Haemostasis. 787-787. 1991
- FIBRIN MODERATES THROMBIN INHIBITION BY ANTITHROMBIN III/HEPARIN BUT NOT THROMBIN INHIBITION BY HEPARIN-COFACTOR II/DERMATAN SULFATE. Thrombosis and Haemostasis. 759-759. 1991
- INHIBITION OF THE AMPLIFICATION REACTIONS OF COAGULATION BY SITE-SPECIFIC INHIBITORS OF ALPHA-THROMBIN. Thrombosis and Haemostasis. 650-650. 1991
- INHIBITION OF THROMBUS GROWTH IS ACHIEVED MORE EFFECTIVELY BY CATALYZING THROMBIN INHIBITION BY DERMATAN SULFATE HEPARIN COFACTOR-II THAN BY HEPARIN ANTITHROMBIN-III. Thrombosis and Haemostasis. 785-785. 1991
- THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPARIN MODERATES FACTOR-VII AND PROTHROMBIN CONSUMPTION ASSOCIATED WITH ELECTIVE KNEE SURGERY. Thrombosis and Haemostasis. 1298-1298. 1991
- COAGULATION AND FIBRINOLYSIS ARE ENHANCED IN SICKLE-CELL DISEASE. The FASEB Journal. A523-A523. 1991
- THE EFFECT OF GLYCOSAMINOGLYCANS ON VESSEL WALL PERMEABILITY IN RABBITS. ADVANCES IN VASCULAR PATHOLOGY 1990, VOL 3. 201-207. 1990
- ACTIVATION OF PLASMA FACTOR-V BY THROMBIN AND FACTOR-XA - INHIBITION BY HIRUDIN AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ANTITHROMBIN-III. Thrombosis and Haemostasis. 33-33. 1989
- ALPHA-2-MACROGLOBULIN MAY PROVIDE PROTECTION FROM THROMBOEMBOLIC EVENTS IN ANTITHROMBIN-III DEFICIENT CHILDREN. Thrombosis and Haemostasis. 382-382. 1989
- HEPARIN, DERMATAN SULFATE AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ATIII INHIBIT COAGULATION BY DELAYING PROTHROMBINASE FORMATION. Thrombosis and Haemostasis. 516-516. 1989
- HEPARIN SENSITIVITY AND RESISTANCE IN THE NEWBORN - AN EXPLANATION. Pediatric Research. A274-A274. 1989
- EFFECTS OF DERMATAN SULFATE AND HEPARIN ON INHIBITION OF THROMBUS GROWTH-INVIVO. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 304-312. 1989
- EFFECTS OF UNFRACTIONATED HEPARIN, DERMATAN SULFATE AND LOW-MOLECULAR WEIGHT HEPARIN ON VESSEL WALL PERMEABILITY IN RABBITS. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 245-254. 1989
- PLASMA ANTICOAGULANT MECHANISMS OF HEPARIN, HEPARAN-SULFATE, AND DERMATAN SULFATE. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 123-131. 1989
- THROMBIN GENERATION IN NEWBORN PLASMA IS DEPENDENT ON PROTHROMBIN CONCENTRATION. Arteriosclerosis. A664-A664. 1988
- ALPHA-2-MACROGLOBULIN IS A MORE IMPORTANT INHIBITOR OF THROMBIN IN INFANT PLASMA THAN IN ADULT PLASMA. Thrombosis and Haemostasis. 400-400. 1987
- HEPARIN IS NOT AN EFFICIENT INHIBITOR OF THE FACTOR XA-DEPENDENT ACTIVATION OF FACTOR-V AND FACTOR-VIII. Thrombosis and Haemostasis. 36-36. 1987
- INCREASED SULFATION IMPROVES THE ABILITY OF VESSEL WALL GLYCOSAMINOGLYCANS TO REGULATE THROMBIN ACTIVITY AND PROTHROMBIN ACTIVATION IN PLASMA. Thrombosis and Haemostasis. 126-126. 1987
- INCREASED SULFATION INCREASES THE BLEEDING SIDE-EFFECTS OF GLYCOSAMINOGLYCANS. Thrombosis and Haemostasis. 7-7. 1987
- THE EFFECTS OF SULFATED POLYSACCHARIDES ON INHIBITION OF THROMBOSIS INDUCED BY DIFFERENT STIMULI. Thrombosis and Haemostasis. 7-7. 1987
- α2-MACROGLOBULIN AND ANTITHROMBIN III ARE EQUALLY IMPORTANT INHIBITORS OF THROMBIN IN NEONATAL PLASMA. Pediatric Research. 306A-306A. 1987
- DDAVP REDUCES THE PLATELET DEFECT ASSOCIATED WITH HEPARIN. Circulation. 95-95. 1986
- DETECTION OF PLASMA INHIBITORS OF THROMBIN. Seminars in Thrombosis and Hemostasis. 341-342. 1986
- INHIBITION OF THROMBIN GENERATION INVITRO REQUIRES LESS HEPARIN IN THE NEWBORN THAN IN THE ADULT. Clinical and Investigative Medicine. A78-A78. 1986
- A DERMATAN SULFATE-LIKE ANTICOAGULANT IN THE FETAL LAMB AFTER ADMINISTRATION OF PK-10169 TO THE EWE. Thrombosis and Haemostasis. 32-32. 1985
- CONTRIBUTIONS OF ANTI-FACTOR-XA AND ANTI-THROMBIN ACTIVITIES OF GLYCOSAMINOGLYCANS (GAGS) TO THEIR ANTICOAGULANT AND ANTITHROMBOTIC PROPERTIES. Thrombosis and Haemostasis. 97-97. 1985
- EVIDENCE THAT INTACT HUMAN-PLATELETS PROVIDE FACTOR VII-LIKE ACTIVITY FOR THE ACTIVATION OF FACTOR-X BY THE EXTRINSIC COAGULATION PATHWAY. Thrombosis and Haemostasis. 176-176. 1985
- HEPARIN AND PENTOSAN POLYSULFATE INHIBIT THE FORMATION OF PROTHROMBINASE AND TENASE COMPLEXES IN PLASMA DEPLETED OF BOTH ANTITHROMBIN III (ATIII) AND HEPARIN COFACTOR-II (HCII). Thrombosis and Haemostasis. 95-95. 1985
- THE HEMORRHAGIC AND ANTITHROMBOTIC EFFECTS OF DERMATAN SULFATE. Thrombosis and Haemostasis. 61-61. 1985
- USE OF POLYCLONAL ANTIBODIES TO FACTOR-VII FOR THE DETECTION OF MONOCLONAL-ANTIBODIES TO FACTOR-VII. Thrombosis and Haemostasis. 263-263. 1985
- ALTERED FETAL LAMB COAGULATION AFTER ADMINISTRATION OF LOW-MOLECULAR WEIGHT HEPARIN TO THE EWE. Circulation. 362-362. 1984
- HEPARIN SULFATE AND DERMATAN SULFATE INHIBIT THROMBIN GENERATION IN PLASMA. Thrombosis and Haemostasis. 226-226. 1983
- RELATIVE CONTRIBUTIONS OF THROMBIN AND ANTITHROMBIN-III AFFINITIES OF HEPARIN FRACTIONS TO THE RATE OF INACTIVATION OF THROMBIN BY ANTITHROMBIN-III. Thrombosis and Haemostasis. 42-42. 1981
- The Effects Of Heparin On The Activation Of Factor X And Prothrombin In Antithrombin III-Depleted Plasma. Thrombosis and Haemostasis. 40-40. 1981
- The Influence Of Heparin, Phospholipid And Platelets On The Thrombin Or Factor Xa Inactivation By Antithrombin III. Thrombosis and Haemostasis. 118-118. 1981
-
journal articles
- An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes. Thrombosis Research. 136:1053-1054. 2015
- Appropriate Assessment of the Functional Consequences of Platelet Cyclooxygenase-1 Inhibition by Aspirin in vivo. Thrombosis Research. 133:697-698. 2014
- Effective, selective and specific inhibition of COX-1 may overcome the “aspirin paradox”. Thrombosis Research. 132:1-2. 2013
-
The fraction of recombinant factor
VIII :Ag unable to bind von Willebrand factor has noFVIII coagulant activity: studies in vitro. Haemophilia. 18:917-925. 2012 - Management of bleeding disorders: basic science. Haemophilia. 18:8-14. 2012
- Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010. Haemophilia. 18:469-475. 2012
- A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Thrombosis and Haemostasis. 107:201-214. 2012
- Immune Responses Associated With Perioperative Exposure and Reexposure to Topical Bovine Thrombin Do Not Impair Hemostasis. Clinical and Applied Thrombosis/Hemostasis. 17:620-632. 2011
- Safety and Efficacy of Thrombin-JMI: A Multidisciplinary Expert Group Consensus. Clinical and Applied Thrombosis/Hemostasis. 17:39-45. 2011
- The United States Food and Drugs Administration Approves a Generic Enoxaparin. Clinical and Applied Thrombosis/Hemostasis. 17:5-8. 2011
- Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism. Thrombosis Research. 124:281-287. 2009
- Recommendations on biosimilar low‐molecular‐weight heparins. Journal of Thrombosis and Haemostasis. 7:1222-1225. 2009
- A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clinical Therapeutics. 31:679-691. 2009
- Early Intraplatelet Signaling Enhances the Release of Human Platelet PAR-1 and -4 Amino-Terminal Peptides in Response to Thrombin. Biochemistry. 48:1562-1572. 2009
- Coordinate Activation of Human Platelet Protease-activated Receptor-1 and -4 in Response to Subnanomolar α-Thrombin. Journal of Biological Chemistry. 283:26886-26893. 2008
- Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate. British Journal of Haematology. 140:589-592. 2008
- Current use of biologicals in thrombosis and haemostasis. Thrombosis and Haemostasis. 99:805-806. 2008
- Differences in the safety profiles of two low-molecular-weight heparins. Thrombosis and Haemostasis. 99:989-990. 2008
- Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thrombosis and Haemostasis. 99:874-882. 2008
- Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases. Thrombosis Research. 123:5-7. 2008
- Plasma-derived biological medicines used to promote haemostasis. Thrombosis and Haemostasis. 99:851-862. 2008
- Propagating factor IX-producing hepatocytes for haemophilia B therapy. Thrombosis and Haemostasis. 99:799-800. 2008
- Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. Journal of Gene Medicine. 9:1002-1010. 2007
- Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. Blood Coagulation and Fibrinolysis. 18:219-225. 2007
- Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Journal of Gene Medicine. 8:362-369. 2006
- Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thrombosis and Haemostasis. 96:568-577. 2006
- Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 70:110-118. 2005
- Statins and Thrombin. Cardiovascular and Hematological Disorders - Drug Targets. 5:115-120. 2005
- Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and Haemostasis. 94:958-964. 2005
- Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates. Haemophilia. 10:459-469. 2004
- Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfusion and Apheresis Science. 28:265-268. 2003
- Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). American Journal of Hematology. 69:192-199. 2002
- Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. Journal of Gene Medicine. 4:215-223. 2002
- Review: The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. Biochemistry (Moscow). 67:56-65. 2002
- The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.. Biochemistry (Moscow). 67:47-55. 2002
- Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia. 7:207-214. 2001
- Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII. Journal of Biological Chemistry. 275:34894-34900. 2000
- HUMAN PLATELET THROMBIN RECEPTORS. Hematology/Oncology Clinics of North America. 14:1185-1198. 2000
- Delivery of recombinant product from subcutaneous implants of encapsulated recombinant cells in canines. Translational Research. 135:484-492. 2000
- Therapeutic approaches for haemophilia. Expert Opinion on Therapeutic Patents. 10:929-938. 2000
- STATIN DRUGS AND DIETARY ISOPRENOIDS AS ANTITHROMBOTIC AGENTS. Hematology/Oncology Clinics of North America. 14:483-490. 2000
- State-of-the-Art-Review : Statins Induce Hypothrombotic States?. Clinical and Applied Thrombosis/Hemostasis. 6:18-21. 2000
- The Cleaved Peptide of PAR1 Results in a Redistribution of the Platelet Surface GPIb-IX-V Complex to the Surface-Connected Canalicular System. Thrombosis and Haemostasis. 84:897-903. 2000
- Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable Microcapsules. Human Gene Therapy. 10:1281-1288. 1999
- Preclinical differentiation of low molecular weight heparins.. Seminars in Thrombosis and Hemostasis. 25 Suppl 3:63-72. 1999
- A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation. Biochemical Journal. 336:283-285. 1998
- PRE‐OPERATIVE FACTOR Xa–TFPI AND POST‐OPERATIVE VENOUS THROMBOSIS. British Journal of Haematology. 101:793-792. 1998
- Pharmacological Actions of Sulodexide. Seminars in Thrombosis and Hemostasis. 24:127-138. 1998
- Thrombin and Antithrombotics. Seminars in Thrombosis and Hemostasis. 24:87-91. 1998
- Platelet activation induced by porcine factor VIII (HYATE:C). American Journal of Hematology. 57:200-205. 1998
- Factor VII Deficiency Caused by a Structural Variant N57D of the First Epidermal Growth Factor Domain. Blood. 91:142-148. 1998
- Binding of Thrombin to the G-protein-linked Receptor, and Not to Glycoprotein Ib, Precedes Thrombin-mediated Platelet Activation. Journal of Biological Chemistry. 272:1997-2004. 1997
- Probable regulation of factor VIIa–tissue factor and prothrombinase by factor Xa–TFPI and TFPI in vivo. British Journal of Haematology. 95:738-746. 1996
- Age‐related changes in factor VII proteolysis in vivo. British Journal of Haematology. 94:407-412. 1996
- Control Mechanisms in Thrombin Generation. Seminars in Thrombosis and Hemostasis. 22:303-308. 1996
- Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 87:5095-5103. 1996
- Plasmin accelerates platelet‐dependent prothrombinase formation without activating the platelets. British Journal of Haematology. 92:458-465. 1996
- Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation. 92:2819-2824. 1995
- Measurement of factor Xa‐antithrombin III in plasma: relationship to prothrombin activation in vivo. British Journal of Haematology. 90:669-680. 1995
- Anticoagulant Actions of Tissue Factor Pathway Inhibitor on Tissue-Factor-Dependent Plasma Coagulation. Seminars in Thrombosis and Hemostasis. 21:240-244. 1995
- α2-Macroglobulin Remains as Important as Antithrombin III for Thrombin Regulation in Cord Plasma in the Presence of Endothelial Cell Surfaces. Pediatric Research. 37:373-378. 1995
- Inhibition of Thrombin by Antithrombin III and Heparin Cofactor II In Vivo. Thrombosis and Haemostasis. 73:405-412. 1995
- Pre-operative Plasma Levels of Thrombin-Antithrombin III Complexes Correlate with the Development of Venous Thrombosis after Major Hip or Knee Surgery. Thrombosis and Haemostasis. 74:602-605. 1995
- Thrombin binding to platelets and their activation in plasma. British Journal of Haematology. 88:592-600. 1994
- Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. Seminars in Thrombosis and Hemostasis. 20:324-327. 1994
- Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II. Thrombosis Research. 74:463-475. 1994
- Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma. Thrombosis and Haemostasis. 72:862-868. 1994
- Is Heparin the Ideal Anticoagulant for Cardiopulmonary Bypass? Dermatan Sulphate May Be an Alternate Choice. Thrombosis and Haemostasis. 71:468-473. 1994
- The hypercoagulable state in cancer patients. Blood Coagulation and Fibrinolysis. 5:S19-23. 1994
- Thrombin Regulation in Children Differs from Adults in the Absence and Presence of Heparin. Thrombosis and Haemostasis. 72:836-842. 1994
- Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. British Journal of Haematology. 85:745-750. 1993
- Understanding Thrombin and Hemostasis. Hematology/Oncology Clinics of North America. 7:1107-1119. 1993
- Expression of Human Factor IX by Microencapsulated Recombinant Fibroblasts. Human Gene Therapy. 4:291-301. 1993
- The direct binding of human factor VII in plasma to recombinant human tissue factor. Thrombosis Research. 70:307-316. 1993
- The effects of heparin and dermatan sulphate on t-PA-induced thrombolysis and blood loss in rabbits. Fibrinolysis and Proteolysis. 7:75-81. 1993
- An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. Thrombosis and Haemostasis. 69:231-235. 1993
- Mechanisms for the Anticoagulant Effects of Synthetic Antithrombins. Advances in Experimental Medicine and Biology. 340:213-226. 1993
- Modulation of intrinsic prothrombin activation by fibrinogen and fibrin I.. Translational Research. 121:64-70. 1993
- Prevention and treatment of thrombosis: novel strategies arising from our understanding the healthy endothelium.. Wiener Klinische Wochenschrift. 105:309-313. 1993
- Prophylactic doses of enoxaparin and heparin inhibit prothrombin activation.. Seminars in Thrombosis and Hemostasis. 19 Suppl 1:29-30. 1993
- Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant?. Thrombosis and Haemostasis. 70:259-262. 1993
- Maturation of the hemostatic system during childhood. Blood. 80:1998-2005. 1992
- Bioregulatory roles for fibrin(ogen) on blood coagulation. Medical Hypotheses. 39:152-155. 1992
- Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent. British Journal of Haematology. 82:400-405. 1992
- The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. British Journal of Haematology. 82:391-399. 1992
- A novel congenital haemostatic defect. Blood Coagulation and Fibrinolysis. 3:357-360. 1992
- Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients. British Journal of Haematology. 81:539-544. 1992
- Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin. Biochemical Journal. 283:893-897. 1992
- Thrombin Inhibition Is Impaired in Plasma of Sick Neonates. Pediatric Research. 31:391-395. 1992
- The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor. FEBS Letters. 298:206-210. 1992
- An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.. Journal of Clinical Investigation. 89:321-326. 1992
- Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849). Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 22:66-72. 1992
- Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. The FEBS Journal. 203:121-125. 1992
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. Thrombosis and Haemostasis. 67:542-544. 1992
- Prevention of Thrombus Growth by Antithrombin III-Dependent and Two Direct Thrombin Inhibitors in Rabbits: Implications for Antithrombotic Therapy. Thrombosis and Haemostasis. 68:424-427. 1992
- Prophylactically Effective Doses of Enoxaparin and Heparin Inhibit Prothrombin Activation. Advances in Experimental Medicine and Biology. 313:231-236. 1992
- Thrombin Regulation in Mother and Fetus During Pregnancy. Seminars in Thrombosis and Hemostasis. 18:81-90. 1992
- Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood. 78:2299-2304. 1991
- Heparin sensitivity and resistance in the neonate: An explanation. Thrombosis Research. 63:85-98. 1991
- Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. Blood. 77:2185-2189. 1991
- Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.. Translational Research. 117:359-364. 1991
- A549 Lung Epithelial Cells Synthesize Anticoagulant Molecules on the Cell Surface and Matrix and in Conditioned Media. American Journal of Respiratory Cell and Molecular Biology. 4:338-346. 1991
- Thrombin structure and function. Blood Coagulation and Fibrinolysis. 2:69-76. 1991
- Modulation of the Enzymatic Activity of α-Thrombin by Polyanions: Consequences on Intrinsic Activation of Factor V and Factor VIII. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 21:240-247. 1991
- Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 21:27-31. 1991
-
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and
d -Phe-Pro-Arg-Ch2Cl. Biochemical Journal. 272:399-406. 1990 - Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. The FEBS Journal. 193:485-493. 1990
- Thrombin after clot formation. Journal of Vascular Surgery. 12:195-196. 1990
- 2 Mechanisms of action of low molecular weight heparins and heparinoids. Best Practice and Research in Clinical Haematology. 3:505-529. 1990
- A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D‐dimer and fibrinogen/fibrin fragment E antigen. British Journal of Haematology. 74:471-479. 1990
- INVITRO AND EXVIVO ACTIVITIES OF CY216 - COMPARISON WITH OTHER LOW-MOLECULAR-WEIGHT HEPARINS. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 20:180-192. 1990
- In vitro and ex vivo Activities of CY216: Comparison with Other Low Molecular Weight Heparins. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 20:180-192. 1990
- Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate. Thrombosis and Haemostasis. 63:271-274. 1990
- The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice. Thrombosis and Haemostasis. 63:413-416. 1990
- Thrombin Generation in Newborn Plasma Is Critically Dependent on the Concentration of Prothrombin. Thrombosis and Haemostasis. 63:027-030. 1990
- The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thrombosis Research. 56:529-539. 1989
- Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo. Annals of the New York Academy of Sciences. 556:304-312. 1989
- Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbitsa. Annals of the New York Academy of Sciences. 556:245-254. 1989
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfatea. Annals of the New York Academy of Sciences. 556:123-131. 1989
- Preface. Annals of the New York Academy of Sciences. 556:xi-xi. 1989
- Anticoagulant Effects of Heparin in Neonatal Plasma'. Pediatric Research. 25:405-408. 1989
- Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. British Journal of Haematology. 71:265-269. 1989
- Alpha-2-Macroglobulin Is an Important Progressive Inhibitor of Thrombin in Neonatal and Infant Plasma. Thrombosis and Haemostasis. 62:1074-1077. 1989
- Effects of Sulfated Polysaccharides on Inhibition of Thrombus Formation initiated by Different Stimuli. Thrombosis and Haemostasis. 61:007-009. 1989
- Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochemical Journal. 257:143-150. 1989
- Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thrombosis Research. 52:517-527. 1988
- Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood. 72:1518-1523. 1988
- Standard assays underestimate the concentration of heparin in neonatal plasma.. Translational Research. 112:641-643. 1988
- Transfusion-Induced Specific Anti–Factor XI Inhibitor in a Patient with Previously Unrecognized Factor XI Deficiency. American Journal of Clinical Pathology. 89:418-422. 1988
- An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition. Thrombosis and Haemostasis. 60:193-198. 1988
- Antithrombotic Properties of Heparin in a Neonatal Piglet Model of Thrombin-Induced Thrombosis. Thrombosis and Haemostasis. 60:289-292. 1988
- Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits. Thrombosis and Haemostasis. 60:188-192. 1988
- Mechanisms for the anticoagulant effect of heparin and related polysaccharides.. Nouvelle Revue Francaise d'Hematologie. 30:155-160. 1988
- Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties. Seminars in Thrombosis and Hemostasis. 14:9-17. 1988
- THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC AND FIBRINOLYTIC DRUGS - A MECHANIC POINT OF VIEW - PREFACE. Seminars in Thrombosis and Hemostasis. 14:U1-U1. 1988
- Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochemical Journal. 248:889-896. 1987
- Evolution of Thrombosis. Annals of the New York Academy of Sciences. 516:586-604. 1987
- The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochemical Journal. 243:579-588. 1987
- Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma. Vox Sanguinis. 52:254-256. 1987
- THE BLOOD-TRANSFUSION EFFECT - CHARACTERIZATION OF T-CELL ALLOANTIGEN-SPECIFIC RECEPTORS BY SERA FROM TRANSFUSED MICE. Transplantation Proceedings. 19:1429-1431. 1987
- The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice.. Transplantation Proceedings. 19:1429-1431. 1987
- Factor VIII concentrate for hemophilia: comparison of two heat-treated products.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 136:150-152. 1987
- Catalysis of Thrombin Inhibition Provides an Index for Estimating the Antithrombotic Potential of Glycosaminoglycans in Rabbits. Thrombosis and Haemostasis. 57:286-293. 1987
- INDUCTION OF ANTIIDIOTYPIC ANTIBODIES BY BLOOD TRANSFUSIONS. Transplantation. 42:632-635. 1986
- Mechanisms for Inhibition of the Generation of Thrombin Activity by Sulfated Polysaccharidesa. Annals of the New York Academy of Sciences. 485:41-55. 1986
- Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. British Journal of Haematology. 64:707-714. 1986
- Lack of Relationship Between Enhanced Bleeding Induced by Heparin and Other Sulfated Polysaccharides and Enhanced Catalysis of Thrombin Inhibition. Seminars in Thrombosis and Hemostasis. 12:324-327. 1986
- The haemorrhagic and antithrombotic effects of dermatan sulphate. British Journal of Haematology. 64:309-317. 1986
- The haemorrhagic and antithrombotic effects of dermatan sulphate.. British Journal of Haematology. 64:309-317. 1986
- Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thrombosis Research. 43:491-495. 1986
- Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?. Antimicrobial Agents and Chemotherapy. 29:1108-1109. 1986
- A Low Molecular Weight Heparin Alters the Fetal Coagulation System in the Pregnant Sheep. Thrombosis and Haemostasis. 55:342-346. 1986
- The immunodepletion of factor VII from human plasma using a monoclonal antibody. British Journal of Haematology. 61:467-475. 1985
- Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth. Thrombosis Research. 40:81-89. 1985
- Approaches to the measurement of the response to Factor VIII concentrate infusion. Thrombosis Research. 39:429-437. 1985
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. British Journal of Haematology. 60:695-704. 1985
- Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate. Seminars in Thrombosis and Hemostasis. 11:133-137. 1985
- Use of Segments for the Quality Control of the Factor VIII: Coagulant Activity of Fresh Frozen Plasma. Vox Sanguinis. 48:213-216. 1985
- Rationale Behind the Development of Low Molecular Weight Heparin Derivatives. Seminars in Thrombosis and Hemostasis. 11:13-16. 1985
- The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 65:198-201. 1985
- North American Study of Factor VIII Concentrate Potency. European Journal of Haematology, Supplement. 33:149-160. 1984
- The isolation of prothrombin, factor IX and factor X from human factor IX concentrates. Thrombosis Research. 36:537-547. 1984
- Assessment of Methods for Cytomegalovirus Antibody Testing of Blood Donations. Vox Sanguinis. 47:343-347. 1984
- Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Biochemistry and Cell Biology. 62:975-983. 1984
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 64:742-747. 1984
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.. Blood. 64:742-747. 1984
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. British Journal of Haematology. 57:229-238. 1984
- Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thrombosis Research. 28:487-497. 1982
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. Thrombosis Research. 23:331-345. 1981
- The factor VIII-independent activation of factor X by factors IXa and VII in plasma. Thrombosis Research. 21:23-33. 1981
- The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thrombosis Research. 20:391-403. 1980
- Immunodepletion of human plasma factor VIII. Blood. 56:604-607. 1980
- Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thrombosis Research. 20:77-83. 1980
- Radloimmunoassay of intestinal goblet cell mucin. Analytical Biochemistry. 83:657-665. 1977
- Hemoglobin Binding by Enzymatic Fragments of Haptoglobin. Biochemistry and Cell Biology. 49:637-640. 1971
- Fragmentation of Haptoglobin by Plasmin. Biochemistry and Cell Biology. 49:90-96. 1971